We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
Read MoreHide Full Article
Quest DiagnosticsIncorporated (DGX - Free Report) is scheduled to report third-quarter 2021 earnings on Oct 21, before the opening bell.
In the last reported quarter, the company’s earnings of $3.18 outpaced the Zacks Consensus Estimate by 2.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 7.5%.
Key Factors to Note
Quest Diagnostics has been benefiting from the two-pronged agenda to accelerate growth and drive operational excellence. Just like other industry participants, the company’s non-COVID base business might have registered a significant sales rebound, as the economy gradually returned to normalcy.
In terms of COVID-19 testing, in the last reported quarter, demand slowed down on mass vaccination drive, resulting in a significant drop in case count, reflecting an industry-wide trend. Nonetheless, from the second half of June, demand stabilized and started to increase modestly, which, Quest Diagnostics believed, was attributable to the emergence of the Delta variant to some extent. Since the middle of July, the company has seen stabilization and a modest increase in PCR volumes. Positivity rates increased in all geographies served by the company’s performing lab in this period.
Quest Diagnostics Incorporated Price and EPS Surprise
This uptrend was maintained through the third quarter. More specifically, in September, Quest Diagnostics noted that starting Jul 22 (its second-quarter earnings release date), COVID-19 molecular testing volumes were stronger than anticipated through the end of August on the Delta variant spike. Taking into account the daily increase in case count through the third quarter, it expects to register strong sequential growth within the COVID-19 diagnostic testing business. In this regard, from Jul 20, 2021 to Sep 28, 2021, the company performed and reported more than 10.7 million COVID-19 molecular diagnostic and antibody serology tests.
In the second quarter, the organic base business exceeded the pre-pandemic comparable level of 2019. With growing contributions from new hospital lab management contracts and people returning to healthcare systems, this trend is expected to have continued through the third quarter. Further, the company is expected to have gained in the third quarter from health plan contracts and tie-ups with hospital health systems. Value-based programs with UnitedHealthcare and Anthem along with a renewed long-standing contractual relationship with one of the largest health plan customers, Aetna, are expected to have contributed to the top line.
In terms of strategic acquisitions, Quest Diagnostics is expected to have secured high returns in the third quarter from acquisitions of Mercy's outreach laboratory services business in Kansas, Mid America Clinical Laboratories in Indiana, and Memorial Hermann Outreach and Blueprint Genetics.
In addition, the company’s flagship laboratory in Clifton, NJ went live on Jan 4, 2021. This highly automated laboratory functioning is also expected to have contributed to its quarterly performance.
Q3 Estimates
For third-quarter 2021, the Zacks Consensus Estimate for total revenues stands at $2.44 billion, indicating a 12.6% dip from the prior-year reported figure. The consensus estimate for earnings is pegged at $2.68, suggesting a year-over-year decline of 37.8%.
Earnings Whispers
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of beating estimates. This is exactly the case as you can see:
Earnings ESP: Quest Diagnostics has an Earnings ESP of +12.10%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these too have the right combination of elements to beat on earnings this reporting cycle.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 2, at present. The company is slated to release third-quarter 2021 results on Oct 27.
West Pharmaceutical Services, Inc. (WST - Free Report) has an Earnings ESP of +1.93% and is a Zacks #2 Ranked stock. The company is slated to release third-quarter 2021 results on Oct 28.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings
Quest Diagnostics Incorporated (DGX - Free Report) is scheduled to report third-quarter 2021 earnings on Oct 21, before the opening bell.
In the last reported quarter, the company’s earnings of $3.18 outpaced the Zacks Consensus Estimate by 2.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 7.5%.
Key Factors to Note
Quest Diagnostics has been benefiting from the two-pronged agenda to accelerate growth and drive operational excellence. Just like other industry participants, the company’s non-COVID base business might have registered a significant sales rebound, as the economy gradually returned to normalcy.
In terms of COVID-19 testing, in the last reported quarter, demand slowed down on mass vaccination drive, resulting in a significant drop in case count, reflecting an industry-wide trend. Nonetheless, from the second half of June, demand stabilized and started to increase modestly, which, Quest Diagnostics believed, was attributable to the emergence of the Delta variant to some extent. Since the middle of July, the company has seen stabilization and a modest increase in PCR volumes. Positivity rates increased in all geographies served by the company’s performing lab in this period.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote
This uptrend was maintained through the third quarter. More specifically, in September, Quest Diagnostics noted that starting Jul 22 (its second-quarter earnings release date), COVID-19 molecular testing volumes were stronger than anticipated through the end of August on the Delta variant spike. Taking into account the daily increase in case count through the third quarter, it expects to register strong sequential growth within the COVID-19 diagnostic testing business. In this regard, from Jul 20, 2021 to Sep 28, 2021, the company performed and reported more than 10.7 million COVID-19 molecular diagnostic and antibody serology tests.
In the second quarter, the organic base business exceeded the pre-pandemic comparable level of 2019. With growing contributions from new hospital lab management contracts and people returning to healthcare systems, this trend is expected to have continued through the third quarter. Further, the company is expected to have gained in the third quarter from health plan contracts and tie-ups with hospital health systems. Value-based programs with UnitedHealthcare and Anthem along with a renewed long-standing contractual relationship with one of the largest health plan customers, Aetna, are expected to have contributed to the top line.
In terms of strategic acquisitions, Quest Diagnostics is expected to have secured high returns in the third quarter from acquisitions of Mercy's outreach laboratory services business in Kansas, Mid America Clinical Laboratories in Indiana, and Memorial Hermann Outreach and Blueprint Genetics.
In addition, the company’s flagship laboratory in Clifton, NJ went live on Jan 4, 2021. This highly automated laboratory functioning is also expected to have contributed to its quarterly performance.
Q3 Estimates
For third-quarter 2021, the Zacks Consensus Estimate for total revenues stands at $2.44 billion, indicating a 12.6% dip from the prior-year reported figure. The consensus estimate for earnings is pegged at $2.68, suggesting a year-over-year decline of 37.8%.
Earnings Whispers
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of beating estimates. This is exactly the case as you can see:
Earnings ESP: Quest Diagnostics has an Earnings ESP of +12.10%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these too have the right combination of elements to beat on earnings this reporting cycle.
Henry Schein, Inc. (HSIC - Free Report) has an Earnings ESP of +0.31% and a Zacks Rank of 2. The company is slated to release third-quarter 2021 results on Nov 1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher Scientific Inc. (TMO - Free Report) has an Earnings ESP of +0.79% and a Zacks Rank of 2, at present. The company is slated to release third-quarter 2021 results on Oct 27.
West Pharmaceutical Services, Inc. (WST - Free Report) has an Earnings ESP of +1.93% and is a Zacks #2 Ranked stock. The company is slated to release third-quarter 2021 results on Oct 28.